Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial.

Shinsuke Hidese, Shintaro Ogawa, Miho Ota, Ikki Ishida, Zenta Yasukawa, Makoto Ozeki, Hiroshi Kunugi

Journal: Nutrients 2020;11(10):2362

PMID: 31623400

Plain Language Summary

plain language summary logo

L-theanine (γ-glutamylethylamide) is a unique non-protein amino acid found in green tea (Camellia sinensis), a widely consumed beverage associated with human health. The aim of this study was to examine the effects of four weeks L-theanine administration (200 mg/day, four weeks) in a healthy population, i.e., individuals without any major psychiatric disorder. This study is a randomized, placebo-controlled, crossover, and double-blind trial. The study enrolled thirty individuals (n = 9 men and n = 21 women). Participants received either an enzymatic synthetic product L-theanine or placebo tablets who had to orally self-administer before sleep each night for four weeks. Results show that four weeks L-theanine administration has positive effects on stress-related symptoms and cognitive function in a healthy population. Furthermore, the reduction in sleep quality problems (disturbances in sleep latency, sleep disturbance and use of sleep medication) was greater in the L-theanine administration compared to the placebo administration, while verbal fluency, especially letter fluency, was improved in the L-theanine administration among individuals who showed relatively low performance at pre-treatment. Authors conclude that L-theanine may be a suitable nutraceutical ingredient for improving mental conditions in a healthy population.

Abstract

This randomized, placebo-controlled, crossover, and double-blind trial aimed to examine the possible effects of four weeks L-theanine administration on stress-related symptoms and cognitive functions in healthy adults. Participants were 30 individuals (nine men and 21 women; age: 48.3 ± 11.9 years) who had no major psychiatric illness. L-theanine (200 mg/day) or placebo tablets were randomly and blindly assigned for four-week administration. For stress-related symptoms, Self-rating Depression Scale, State-Trait Anxiety Inventory-trait, and Pittsburgh Sleep Quality Index (PSQI) scores decreased after L-theanine administration ( = 0.019, 0.006, and 0.013, respectively). The PSQI subscale scores for sleep latency, sleep disturbance, and use of sleep medication reduced after L-theanine administration, compared to the placebo administration (all < 0.05). For cognitive functions, verbal fluency and executive function scores improved after L-theanine administration ( = 0.001 and 0.031, respectively). Stratified analyses revealed that scores for verbal fluency ( = 0.002), especially letter fluency ( = 0.002), increased after L-theanine administration, compared to the placebo administration, in individuals who were sub-grouped into the lower half by the median split based on the mean pretreatment scores. Our findings suggest that L-theanine has the potential to promote mental health in the general population with stress-related ailments and cognitive impairments.

Address: Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan. [email protected].; Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan. [email protected].; Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan. [email protected].; Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan. [email protected].; Department of Research and Development, Nutrition Division, Taiyo Kagaku Co. Ltd, 1-3, Takara-machi, Yokkaichi, Mie 510-0844, Japan. [email protected].; Department of Research and Development, Nutrition Division, Taiyo Kagaku Co. Ltd, 1-3, Takara-machi, Yokkaichi, Mie 510-0844, Japan. [email protected].; Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1, Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan. [email protected].

Physical Environment

Clinical Imbalances

Laboratory Testing

Modifiable Lifestyle Factors

Jadad Score

Allocation Concealment

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.